Reithera S.R.L.
Castel Romano, Lazio
- UEI
- WQ6HX86PD4B6
- CAGE
- AJ907
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Via di Castel Romano, 100, 00128 Roma RM, Italy
- Website
- reithera.com
- Founded
- 2005
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 3 batches of CHAD3 vector expressing ebola and marburg antigens at the scale of 2L | National Institute of Allergy and Infectious Diseases (NIH) | $71,400 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Albert B. Sabin Vaccine Institute, Inc. (The) | 75A50123C00010 | $2,369,000 | |
| Albert B. Sabin Vaccine Institute, Inc. (The) | 75A50123C00010 | $474,000 | |
| Albert B. Sabin Vaccine Institute, Inc. (The) | 75A50123C00010 | $10,700,000 | |
| Albert B. Sabin Vaccine Institute, Inc. (The) | 75A50123C00010 | $11,050,000 |
Similar vendors
About the company
Reithera S.R.L., an Italy-based foreign-owned limited liability partnership, manufactures viral vector vaccine candidates and bulk drug substances for federal biodefense and infectious disease preparedness programs, operating primarily as a subcontractor (80% of recent awards) with one direct prime award to the National Institute of Allergy and Infectious Diseases.
Reithera's footprint is narrow and specialized. The vendor has executed five federal awards since 2021 with combined potential value of $71 thousand but obligated dollars of $24.7 million — a stark disparity driven by the sub-award structure and the nature of vaccine manufacturing contracts. All customer activity concentrates with the Department of Health and Human Services: one $71.4 thousand prime purchase order from NIAID (September 2021) for three batches of CHAD3 vector expressing Ebola and Marburg antigens at two-liter scale, and four sub-awards from the Office of the Assistant Secretary for Preparedness and Response (ASPR) issued between March 2023 and November 2024. Across these sub-awards under prime contractor Albert B. Sabin Vaccine Institute, Inc., Reithera provides bulk drug substance manufacturing and fill-finish operations for Sudan ebolavirus and Marburg virus vaccine candidates under the broader Sabin Sudan Ebolavirus Vaccine program. The vendor's award portfolio splits across two NAICS categories — Research and Development in Biotechnology (4 awards) and Biological Product Manufacturing (1 award) — with a Drugs and Biologicals PSC footprint.
Activity pattern shows intermittent engagement: one award in 2021, two in 2023, and two in 2024, with the most recent sub-award issued November 2024. The obligated-to-potential-value ratio (34,544%) reflects the scaled nature of manufacturing programs, where initial ceiling values on POs and subcontracts are substantially exceeded by production orders. Reithera appears on two SCI records in FY2024 as a named subcontractor, representing 10.8 FTEs delivered under sub-agreements; this figure is a narrow slice of the vendor's federal footprint and excludes the higher-dollar manufacturing work captured outside the $150,000 SCI reporting threshold. Reithera's federal presence is entirely reactive — driven by ASPR and NIH procurement demand for viral vector manufacturing capacity for pandemic and biodefense vaccine development, with no IDV seat, BPA position, or standing contract vehicle footprint.
Quick answers
Is Reithera S.R.L. registered in SAM.gov?
Yes. Reithera S.R.L.'s SAM.gov registration is active through January 8, 2027.
What is Reithera S.R.L.'s most recent federal award?
Reithera S.R.L.'s most recent federal contract award is 3 batches of CHAD3 vector expressing ebola and marburg antigens at the scale of 2L (75N93021P01370), from National Institute of Allergy and Infectious Diseases (NIH), on September 9, 2021.
On GovTribe
See Reithera S.R.L.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors